SPC
VKTX icon

Sigma Planning Corp’s Viking Therapeutics VKTX Stock Holding History

Sigma Planning Corp’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$446K Buy
13,700
+5,940
+77% +$191K 0.01% 885
2025
Q4 		$273K Buy
+7,760
New +$275K 0.01% 1080
2024
Q4 		– Sell
-15,119
Closed -$957K – 1257
2024
Q3 		$957K Buy
+15,119
New +$887K 0.03% 517

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Sigma Planning Corp's VKTX Position: Q1 2026 in Review

Sigma Planning Corp increased its Viking Therapeutics (VKTX) stake by 77% in Q1 2026, buying an estimated $191K and bringing the position to 13,700 shares worth $446K. The position accounts for 0.01% of the portfolio, ranked #885.

Sigma Planning Corp first reported a position in VKTX in Q3 2024 and has held it in 3 quarters since. The position peaked at $957K in Q3 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Sigma Planning Corp held 13,700 shares of Viking Therapeutics worth $446K as of Q1 2026.
  • Sigma Planning Corp bought 5,940 Viking Therapeutics shares in Q1 2026, an estimated $191K.
  • Viking Therapeutics made up 0.01% of Sigma Planning Corp's portfolio in Q1 2026, its #885 holding.
  • Sigma Planning Corp first reported a position in Viking Therapeutics in Q3 2024 and has held it in 3 quarters since.
  • Sigma Planning Corp's Viking Therapeutics position peaked at $957K in Q3 2024.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Sigma Planning Corp's 13F filing for Q1 2026, filed 4 May 2026.